Abstract

The increasing demand for immune cell applications, both in clinical settings and in research laboratories, has highlighted the critical need for cryopreservation (banking) methods for T cells. While conventional techniques such as freezing with liquid nitrogen remain prevalent, they pose significant challenges including high equipment costs, safety considerations, and logistical hurdles in transportation. Our cryopreservation medium, C80EZ®, represents a novel approach, leveraging biocompatible polysaccharides as cryoprotectants to enable safe storage at −80°C. This paper presents a comprehensive series of tests assessing the effectiveness of C80EZ® in shielding T cells from the detrimental effects of cryopreservation. Importantly, our findings demonstrate that C80EZ® not only ensures the survival of T cells, with a particular emphasis on preserving the CD8+ subsets, but also maintains their critical function in targeting and eliminating cancer cells.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.